235 related articles for article (PubMed ID: 27340749)
1. Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
Thurberg BL; Wasserstein MP; Jones SA; Schiano TD; Cox GF; Puga AC
Am J Surg Pathol; 2016 Sep; 40(9):1232-42. PubMed ID: 27340749
[TBL] [Abstract][Full Text] [Related]
2. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
Wasserstein MP; Jones SA; Soran H; Diaz GA; Lippa N; Thurberg BL; Culm-Merdek K; Shamiyeh E; Inguilizian H; Cox GF; Puga AC
Mol Genet Metab; 2015; 116(1-2):88-97. PubMed ID: 26049896
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
Thurberg BL; Diaz GA; Lachmann RH; Schiano T; Wasserstein MP; Ji AJ; Zaher A; Peterschmitt MJ
Mol Genet Metab; 2020; 131(1-2):245-252. PubMed ID: 32620536
[TBL] [Abstract][Full Text] [Related]
4. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
Wasserstein MP; Diaz GA; Lachmann RH; Jouvin MH; Nandy I; Ji AJ; Puga AC
J Inherit Metab Dis; 2018 Sep; 41(5):829-838. PubMed ID: 29305734
[TBL] [Abstract][Full Text] [Related]
5. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B).
Thurberg BL; Wasserstein MP; Schiano T; O'Brien F; Richards S; Cox GF; McGovern MM
Am J Surg Pathol; 2012 Aug; 36(8):1234-46. PubMed ID: 22613999
[TBL] [Abstract][Full Text] [Related]
6. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial.
Wasserstein MP; Lachmann R; Hollak C; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Hennermann JB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Thurberg BL; Yarramaneni A; Armstrong NM; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Dec; 18(1):378. PubMed ID: 38042851
[TBL] [Abstract][Full Text] [Related]
7. Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).
McGovern MM; Wasserstein MP; Kirmse B; Duvall WL; Schiano T; Thurberg BL; Richards S; Cox GF
Genet Med; 2016 Jan; 18(1):34-40. PubMed ID: 25834946
[TBL] [Abstract][Full Text] [Related]
8. Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency.
Raebel EM; Wiseman S; Donnelly C; Mathieson T; Pountney J; Crowe J; Hopkin J
Orphanet J Rare Dis; 2024 Feb; 19(1):36. PubMed ID: 38303068
[TBL] [Abstract][Full Text] [Related]
9. Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.
Lachmann RH; Diaz GA; Wasserstein MP; Armstrong NM; Yarramaneni A; Kim Y; Kumar M
Orphanet J Rare Dis; 2023 Apr; 18(1):94. PubMed ID: 37098529
[TBL] [Abstract][Full Text] [Related]
10. Olipudase Alfa in Non-CNS Manifestations of Acid Sphingomyelinase Deficiency: A Profile of Its Use.
Syed YY
Clin Drug Investig; 2023 May; 43(5):369-377. PubMed ID: 37133675
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results.
Diaz GA; Giugliani R; Guffon N; Jones SA; Mengel E; Scarpa M; Witters P; Yarramaneni A; Li J; Armstrong NM; Kim Y; Ortemann-Renon C; Kumar M
Orphanet J Rare Dis; 2022 Dec; 17(1):437. PubMed ID: 36517856
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Wasserstein M; Lachmann R; Hollak C; Arash-Kaps L; Barbato A; Gallagher RC; Giugliani R; Guelbert NB; Ikezoe T; Lidove O; Mabe P; Mengel E; Scarpa M; Senates E; Tchan M; Villarrubia J; Chen Y; Furey S; Thurberg BL; Zaher A; Kumar M
Genet Med; 2022 Jul; 24(7):1425-1436. PubMed ID: 35471153
[TBL] [Abstract][Full Text] [Related]
13. Olipudase Alfa: First Approval.
Keam SJ
Drugs; 2022 Jun; 82(8):941-947. PubMed ID: 35639287
[TBL] [Abstract][Full Text] [Related]
14. Changes in PCSK 9 and apolipoprotein B100 in Niemann-Pick disease after enzyme replacement therapy with olipudase alfa.
Garside B; Ho JH; Kwok S; Liu Y; Dhage S; Donn R; Iqbal Z; Jones SA; Soran H
Orphanet J Rare Dis; 2021 Feb; 16(1):107. PubMed ID: 33639994
[TBL] [Abstract][Full Text] [Related]
15. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.
Diaz GA; Jones SA; Scarpa M; Mengel KE; Giugliani R; Guffon N; Batsu I; Fraser PA; Li J; Zhang Q; Ortemann-Renon C
Genet Med; 2021 Aug; 23(8):1543-1550. PubMed ID: 33875845
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic lipid profile in patients with Niemann-Pick disease type B: What treatment strategies?
Maines E; Franceschi R; Rizzardi C; Deodato F; Piccoli G; Gragnaniello V; Burlina A; Soffiati M
J Clin Lipidol; 2022; 16(2):143-154. PubMed ID: 35181260
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy for children with acid sphingomyelinase deficiency in the real world: A single center experience in Taiwan.
Pan YW; Tsai MC; Yang CY; Yu WH; Wang B; Yang YJ; Chou YY
Mol Genet Metab Rep; 2023 Mar; 34():100957. PubMed ID: 36873248
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology.
Kaddi CD; Niesner B; Baek R; Jasper P; Pappas J; Tolsma J; Li J; van Rijn Z; Tao M; Ortemann-Renon C; Easton R; Tan S; Puga AC; Schuchman EH; Barrett JS; Azer K
CPT Pharmacometrics Syst Pharmacol; 2018 Jul; 7(7):442-452. PubMed ID: 29920993
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.
Ziegler RJ; Brown C; Barbon CM; D'Angona AM; Schuchman EH; Andrews L; Thurberg BL; McPherson JM; Karey KP; Cheng SH
Mol Genet Metab; 2009 May; 97(1):35-42. PubMed ID: 19231265
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
